News Novo Nordisk cuts Wegovy price ahead of TrumpRx launch Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.
News Novo, Lilly sign MFN pricing deal with Trump administration The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
News Novo Nordisk cuts guidance again on weaker GLP-1 growth Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.
News Novo Nordisk cuts GLP-1 prices for cash buyers Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.
News Novo Nordisk weakens again on interim results readout Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.
News Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
